In Re: Zofran (Ondansetron)Products Liability Litigation

Track this case

Case overview

Case Number:

1:15-md-02657

Court:

Massachusetts

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

F. Dennis Saylor, IV

Firms

Companies

Sectors & Industries:

  1. October 06, 2016

    Familes Blast GSK's New Zofran Label Submission In MDL

    Families in multidistrict litigation over GlaxoSmithKline's anti-nausea drug Zofran on Thursday told a Massachusetts federal court that a 2016 label update shows that it was, in fact, possible to show additional warnings on a previous label beyond what had been approved by regulators, contrary to the company's assertions.

  2. October 05, 2016

    Parents Slam Bid To Toss GSK Zofran Suit From MDL

    A set of parents in multidistrict litigation over GlaxoSmithKline’s anti-nausea drug Zofran struck back on Tuesday at a bid to include their suit in a consolidated dismissal motion, saying they’ve gone above and beyond to make sure certain of their documents were correctly filed.

  3. February 22, 2016

    GSK Wants To Know If MDL Plaintiffs Took Generic Zofran

    GlaxoSmithKline urged a Massachusetts' federal court on Monday to require all plaintiffs in multidistrict litigation over anti-nausea drug Zofran to identify whether they used the brand-name drug or its generic equivalent, saying that doing so will allow the court to assess the viability of individual cases.

  4. January 06, 2016

    Families Say Animal Studies Back Their Claims In Zofran MDL

    Families who claim that GlaxoSmithKline's "off label" promotion of its anti-nausea drug Zofran for morning sickness led to birth defects urged the Massachusetts federal judge overseeing the multidistrict litigation on Wednesday not to dismiss their claims, pointing to animal studies they say support their allegations.

  5. October 13, 2015

    JPML Consolidates Birth Defect Suits Over GSK's Zofran

    The U.S. Judicial Panel on Multidistrict Litigation on Tuesday consolidated in Massachusetts district court a number of lawsuits alleging GlaxoSmithKline's "off label" promotion of its anti-nausea drug Zofran for morning sickness led to birth defects, saying five similar actions are pending in the court already, including the first-filed complaint.